Xencor, Inc. News Releases https://investors.xencor.com/ Xencor, Inc. News Releases en Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development https://investors.xencor.com/news-releases/news-release-details/xencor-appoints-jeremy-grunstein-phd-vice-president-business MONROVIA, Calif. --(BUSINESS WIRE)--May 23, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein Thu, 23 May 2019 08:01:00 -0400 Xencor, Inc. News Releases 11276 Xencor Reports First Quarter 2019 Financial Results https://investors.xencor.com/news-releases/news-release-details/xencor-reports-first-quarter-2019-financial-results -- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 9, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic Thu, 09 May 2019 16:00:00 -0400 Xencor, Inc. News Releases 11256 Xencor to Present at Upcoming Investor Conferences https://investors.xencor.com/news-releases/news-release-details/xencor-present-upcoming-investor-conferences-10 MONROVIA, Calif. --(BUSINESS WIRE)--May 8, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will present Wed, 08 May 2019 16:01:00 -0400 Xencor, Inc. News Releases 11241 Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors https://investors.xencor.com/news-releases/news-release-details/xencor-doses-first-patient-phase-1-study-xmabr23104-treatment — XmAb23104, a PD-1 x ICOS bispecific antibody, is the sixth XmAb ® antibody engineered with Xencor’s bispecific Fc domain to enter clinical development — MONROVIA, Calif. --(BUSINESS WIRE)--May 6, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered Mon, 06 May 2019 08:01:00 -0400 Xencor, Inc. News Releases 11231 Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 https://investors.xencor.com/news-releases/news-release-details/xencor-host-first-quarter-2019-financial-results-webcast-and MONROVIA, Calif. --(BUSINESS WIRE)--May 2, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter Thu, 02 May 2019 16:01:00 -0400 Xencor, Inc. News Releases 11221 Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 https://investors.xencor.com/news-releases/news-release-details/xencor-announces-partial-clinical-hold-lifted-phase-1-study MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S. Tue, 30 Apr 2019 08:01:00 -0400 Xencor, Inc. News Releases 11206 Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program https://investors.xencor.com/news-releases/news-release-details/xencor-and-astellas-enter-collaboration-novel-bispecific -- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Xencor, Inc. Tue, 02 Apr 2019 08:01:00 -0400 Xencor, Inc. News Releases 11191 Xencor to Participate in Upcoming Investor Conferences https://investors.xencor.com/news-releases/news-release-details/xencor-participate-upcoming-investor-conferences-0 MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will Mon, 01 Apr 2019 16:05:00 -0400 Xencor, Inc. News Releases 11186 Xencor Announces Closing of Research Collaboration and License Agreement with Genentech https://investors.xencor.com/news-releases/news-release-details/xencor-announces-closing-research-collaboration-and-license MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research Fri, 08 Mar 2019 08:01:00 -0500 Xencor, Inc. News Releases 11156 Xencor Reports Fourth Quarter and Full Year 2018 Financial Results https://investors.xencor.com/news-releases/news-release-details/xencor-reports-fourth-quarter-and-full-year-2018-financial - Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA - - Research and License Agreement for XmAb®24306 and IL-15 Cytokines Provides $120 Million Mon, 25 Feb 2019 16:24:00 -0500 Xencor, Inc. News Releases 11131